ArticleScience translational medicine2011
Dissecting the immune cell mayhem that drives lupus pathogenesis.
Article in Science translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus.Blood · 2020Article
- Utilization of Biomarkers in Lupus Nephritis.Advances in chronic kidney disease · 2019Review
- Evaluation of the serum β2 Microglobulin level in patients with systemic lupus erythematosus and its correlation with disease activity.BioMedicine · 2019Article
- Female predisposition to TLR7-driven autoimmunity: gene dosage and the escape from X chromosome inactivation.Seminars in immunopathology · 2019Review
- Precision medicine in lupus nephritis: can biomarkers get us there?Translational research : the journal of laboratory and clinical medicine · 2018Review
- Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.Frontiers in immunology · 2018Article
- Re-Examining Neutrophil Participation in GN.Journal of the American Society of Nephrology : JASN · 2017Review
- Neutrophil Extracellular Traps, Antiphospholipid Antibodies and Treatment.Antibodies (Basel, Switzerland) · 2017Review
- Taking the STING out of TLR-driven autoimmune diseases: good, bad, or indifferent?Journal of leukocyte biology · 2017Review
- Galectin-3 in autoimmunity and autoimmune diseases.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- Suppression of systemic autoimmunity by the innate immune adaptor STING.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Types of DNA methylation status of the interspersed repetitive sequences for LINE-1, Alu, HERV-E and HERV-K in the neutrophils from systemic lupus erythematosus patients and healthy controls.Journal of human genetics · 2014Article
- The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease.Journal of immunology research · 2014Review
- The pathogenesis of systemic lupus erythematosus-an update.Current opinion in immunology · 2012Review
- NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus.Science translational medicine · 2012Article
- Neutrophil extracellular traps: is immunity the second function of chromatin?The Journal of cell biology · 2012Review
- Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- SLE in 2011: Deciphering the role of NETs and networks in SLE.Nature reviews. Rheumatology · 2012Review
- The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.The open rheumatology journal · 2012Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The autoimmune disease systemic lupus erythematosus (SLE) results from an inability of the immune system to discriminate between certain self-antigens and foreign ones. The most common treatment of SLE involves the use of immunosuppressive drugs to reduce inflammation, but these therapies have serious side effects. Three recent papers in Science Translational Medicine redirect focus on neutrophils, platelets, and interferon-α in the pathogenesis of SLE and reinforce the notion that researchers should seek to discover and devise combination therapies that target these processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.